Hypoxia inducible BHLHB2 is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma

Biochemical and Biophysical Research Communications

Volumn 401, Issue 3, 2010, Pages 422-428

  Wang, Weibin ^a   Reiser Erkan, Carolin ^a   Michalski, Christoph W ^a   Raggi, Matthias C ^a   Quan, Liao ^b   Yupei, Zhao ^b   Friess, Helmut ^a   Erkan, Mert ^a   Kleeff, Jörg ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Chemoresistance; DEC1; Gemcitabine; Hypoxia; Marker; SHARP2

Indexed keywords

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CASPASE 3; CYCLIC AMP; DACTINOMYCIN; GEMCITABINE; SMALL INTERFERING RNA; TRANSCRIPTIONAL FACTOR BHLHB2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL INVASION; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL TIME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, PANCREATIC DUCTAL; CELL HYPOXIA; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MALE; PANCREAS; PANCREATIC NEOPLASMS; PROGNOSIS; RNA INTERFERENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 77958153013     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.09.070     Document Type: Article

References (35)

1. Li Y., Zhang H., Xie M., Hu M., Ge S., Yang D., Wan Y., Yan B. Abundant expression of Dec1/stra13/sharp2 in colon carcinoma: its antagonizing role in serum deprivation-induced apoptosis and selective inhibition of procaspase activation. Biochem. J. 2002, 367:413-422.
2. Chakrabarti J., Turley H., Campo L., Han C., Harris A.L., Gatter K.C., Fox S.B. The transcription factor DEC1 (stra13, SHARP2) is associated with the hypoxic response and high tumour grade in human breast cancers. Br. J. Cancer 2004, 91:954-958.
3. Zheng Y., Jia Y., Wang Y., Wang M., Li B., Shi X., Ma X., Xiao D., Sun Y. The hypoxia-regulated transcription factor DEC1 (Stra13, SHARP-2) and its expression in gastric cancer. Omics 2009, 13:301-306.
4. Ivanova A., Liao S.Y., Lerman M.I., Ivanov S., Stanbridge E.J. STRA13 expression and subcellular localisation in normal and tumour tissues: implications for use as a diagnostic and differentiation marker. J. Med. Genet. 2005, 42:565-576.
5. Giatromanolaki A., Koukourakis M.I., Sivridis E., Turley H., Wykoff C.C., Gatter K.C., Harris A.L. DEC1 (STRA13) protein expression relates to hypoxia-inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer. J. Pathol. 2003, 200:222-228.
6. Ivanova A.V., Ivanov S.V., Danilkovitch-Miagkova A., Lerman M.I. Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway. J. Biol. Chem. 2001, 276:15306-15315.
7. Ivanova A.V., Ivanov S.V., Zhang X., Ivanov V.N., Timofeeva O.A., Lerman M.I. STRA13 interacts with STAT3 and modulates transcription of STAT3-dependent targets. J. Mol. Biol. 2004, 340:641-653.
8. Zawel L., Yu J., Torrance C.J., Markowitz S., Kinzler K.W., Vogelstein B., Zhou S. DEC1 is a downstream target of TGF-beta with sequence-specific transcriptional repressor activities. Proc. Natl. Acad. Sci. USA 2002, 99:2848-2853.
9. Guillaumond F., Lacoche S., Dulong S., Grechez-Cassiau A., Filipski E., Li X.M., Levi F., Berra E., Delaunay F., Teboul M. Altered Stra13 and Dec2 circadian gene expression in hypoxic cells. Biochem. Biophys. Res. Commun. 2008, 369:1184-1189.
10. Noshiro M., Usui E., Kawamoto T., Sato F., Nakashima A., Ueshima T., Honda K., Fujimoto K., Honma S., Honma K., Makishima M., Kato Y. Liver X receptors (LXRalpha and LXRbeta) are potent regulators for hepatic Dec1 expression. Genes Cells 2009, 14:29-40.
11. Sato F., Bhawal U.K., Kawamoto T., Fujimoto K., Imaizumi T., Imanaka T., Kondo J., Koyanagi S., Noshiro M., Yoshida H., Kusumi T., Kato Y., Kijima H. Basic-helix-loop-helix (bHLH) transcription factor DEC2 negatively regulates vascular endothelial growth factor expression. Genes Cells 2008, 13:131-144.
12. Sun H., Lu B., Li R.Q., Flavell R.A., Taneja R. Defective T cell activation and autoimmune disorder in Stra13-deficient mice. Nat. Immunol. 2001, 2:1040-1047.
13. Lennon D.P., Edmison J.M., Caplan A.I. Cultivation of rat marrow-derived mesenchymal stem cells in reduced oxygen tension: effects on in vitro and in vivo osteochondrogenesis. J. Cell Physiol. 2001, 187:345-355.
14. Yun Z., Maecker H.L., Johnson R.S., Giaccia A.J. Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia. Dev. Cell 2002, 2:331-341.
15. Yoon D.Y., Buchler P., Saarikoski S.T., Hines O.J., Reber H.A., Hankinson O. Identification of genes differentially induced by hypoxia in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 2001, 288:882-886.
16. Erkan M., Michalski C.W., Rieder S., Reiser-Erkan C., Abiatari I., Kolb A., Giese N.A., Esposito I., Friess H., Kleeff J. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin. Gastroenterol. Hepatol. 2008, 6:1155-1161.
17. Erkan M., Reiser-Erkan C., Michalski C.W., Deucker S., Sauliunaite D., Streit S., Esposito I., Friess H., Kleeff J. Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia 2009, 11:497-508.
18. Michalski C.W., Gorbachevski A., Erkan M., Reiser C., Deucker S., Bergmann F., Giese T., Weigand M., Giese N.A., Friess H., Kleeff J. Mononuclear cells modulate the activity of pancreatic stellate cells which in turn promote fibrosis and inflammation in chronic pancreatitis. J. Transl. Med. 2007, 5:63.
19. Reiser-Erkan C., Erkan M., Pan Z., Bekasi S., Giese N.A., Streit S., Michalski C.W., Friess H., Kleeff J. Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol. Ther. 2008, 7:1352-1359.
20. Erkan M., Kleeff J., Gorbachevski A., Reiser C., Mitkus T., Esposito I., Giese T., Buchler M.W., Giese N.A., Friess H. Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology 2007, 132:1447-1464.
21. Erkan M., Kleeff J., Esposito I., Giese T., Ketterer K., Buchler M.W., Giese N.A., Friess H. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 2005, 24:4421-4432.
22. Michalski C.W., Erkan M., Sauliunaite D., Giese T., Stratmann R., Sartori C., Giese N.A., Friess H., Kleeff J. Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br. J. Cancer 2008, 99:760-767.
23. Kleeff J., Kornmann M., Sawhney H., Korc M. Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells. Int. J. Cancer 2000, 86:399-407.
24. Pan Z., Erkan M., Streit S., Friess H., Kleeff J. Silencing of GRP94 expression promotes apoptosis in pancreatic cancer cells. Int. J. Oncol. 2009, 35:823-828.
25. Tran P.T., Felsher D.W. The current STATe of biomarkers to predict the response to anti-angiogenic therapies. Cancer Biol. Ther. 2008, 7:2004-2006.
26. Couvelard A., O'Toole D., Leek R., Turley H., Sauvanet A., Degott C., Ruszniewski P., Belghiti J., Harris A.L., Gatter K., Pezzella F. Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology 2005, 46:668-676.
27. Kisker O., Onizuka S., Banyard J., Komiyama T., Becker C.M., Achilles E.G., Barnes C.M., O'Reilly M.S., Folkman J., Pirie-Shepherd S.R. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res. 2001, 61:7298-7304.
28. Michalski C.W., Maier M., Erkan M., Sauliunaite D., Bergmann F., Pacher P., Batkai S., Giese N.A., Giese T., Friess H., Kleeff J. Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells. PLoS One 2008, 3:e1701.
29. Esposito I., Seiler C., Bergmann F., Kleeff J., Friess H., Schirmacher P. Hypothetical progression model of pancreatic cancer with origin in the centroacinar-acinar compartment. Pancreas 2007, 35:212-217.
30. Wykoff C.C., Pugh C.W., Maxwell P.H., Harris A.L., Ratcliffe P.J. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 2000, 19:6297-6305.
31. Shapland C., Lowings P., Lawson D. Identification of new actin-associated polypeptides that are modified by viral transformation and changes in cell shape. J. Cell Biol. 1988, 107:153-161.
32. Fisher A.L., Ohsako S., Caudy M. The WRPW motif of the hairy-related basic helix-loop-helix repressor proteins acts as a 4-amino-acid transcription repression and protein-protein interaction domain. Mol. Cell. Biol. 1996, 16:2670-2677.
33. Streit S., Michalski C.W., Erkan M., Friess H., Kleeff J. Confirmation of DNA microarray-derived differentially expressed genes in pancreatic cancer using quantitative RT-PCR. Pancreatology 2009, 9:577-582.
34. Erkan M., Weis N., Pan Z., Schwager C., Samkharadze T., Jiang X., Wirkner U., Giese N.A., Ansorge W., Debus J., Huber P.E., Friess H., Abdollahi A., Kleeff J. Organ-, inflammation- and cancer specific transcriptional fingerprints of pancreatic and hepatic stellate cells. Mol. Cancer 2010, 9:88.
35. UICC, TNM classification of malignant tumors, sixth ed., John Wiley & Sons, 2002.